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Abstract:  6 
Background: The survival and prognostic factors in non-metastatic, radiation-induced 7 
bone sarcomas of bone have not been described. Moreover, the quantitative data about 8 
surgical outcomes and complications after limb-salvage surgery versus amputation are 9 
quite limited. 10 
Methods: Twenty-five patients with non-metastatic, radiation- nduced sarcoma of bone 11 
who underwent definitive surgery were analysed. Histological diagnosis was 12 
osteosarcoma in 19 and undifferentiated pleomorphic sar oma in six. The definitive 13 
surgery was limb-salvage surgery in 15 patients and an amputation in 10.  14 
Results: The 5-year overall survival rate (OS) and the 5-year event-free survival rate 15 
(EFS) were 53% (95% CI 31% to 70%) and 40% (21% to 59%), respectively. Patients 16 
with wide or radical surgical margins (n = 13) showed significantly better OS compared 17 
with those with marginal (n = 8) or intralesional (n = 2) margins (5-year OS, radical or 18 
wide = 74%, marginal = 17%, intralesional = 0%, p =0.044). The risk of local recurrence 19 
was significantly higher in the limb-salvage group compared to the amputation group 20 
(49% vs 0%, p = 0.011). OS and EFS were not significantly different between 21 
limb-salvage group and an amputation group (p = 0.188 and 0.912, respectively). 22 
Conclusions: We believe non-metastatic, radiation-induced sarcoma f bone should be 23 
 3
resected with the aim of achieving wide or radical margins. Although limb-salvage 24 
surgery was related to higher rates of local recurrence compared with those of the 25 
amputation group, OS and EFS were not different among two groups. Surgeons need to 26 
discuss the higher risk of local recurrence in limb-salvage surgery.  27 
 28 
Keywords: Radiation-induced sarcoma of bone, Surgical outcomes, Prognosis 29 
  30 
 4
1. Introduction  31 
Radiation-induced sarcoma of bone is a rare sarcoma that develops in a previously 32 
irradiated field after median latency of 10 years [1-5]. The link between radiation and 33 
bone sarcomas was first established by Martland et al. [6] in 1929.  34 
We have previously reported a poor prognosis in radiation-induced bone 35 
sarcomas, especially for patients with metastasis at presentation [7], which has been 36 
substantiated by several authors [3, 8]. However, th  survival and prognostic factors in 37 
non-metastatic, radiation-induced bone sarcomas of bone have not been described. 38 
It has been suggested that pre-operative chemotherapy followed by surgery 39 
may improve survival [9-11]. Surgery for these patien s is frequently challenging due to 40 
the effects of previous irradiation on surrounding tissues causing, a loss of clear 41 
distinction between anatomical planes, which can compr mise cross sectional imaging 42 
and complicate surgical margins [12, 13]. Irradiation also reduces the proliferative 43 
capacity of normal tissues leading to poor wound healing and wound site infection [14, 44 
15]. As a result, primary amputation was favoured for patients with radiation-induced 45 
bone sarcoma in several reports [3,4,13,16,17]. However, the quantitative data about 46 
surgical outcomes and complications after limb-salvage surgery versus amputation are 47 
quite limited.  48 
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We therefore aimed to determine surgical and oncological outcomes and 49 
prognostic factors of non-metastatic, radiation-induced sarcoma of bone. Surgical and 50 
oncological outcomes were also compared between those patients that underwent 51 
limb-salvage and amputation. This data can guide clinicians when deciding on an 52 
optimal surgical treatment strategy in non-metastatic, resectable, radiation-induced 53 
sarcoma. 54 
 55 
2. Patients and Methods 56 
We identified 47 patients with a radiation-induced bone sarcoma from our oncology 57 
database between 1987 and 2017. Inclusion criteria r quired patients to be free of 58 
metastatic disease at initial presentation and to have undergone definitive surgery. 59 
Twenty-two patients were excluded due to: metastasis t diagnosis (n = 8), received 60 
only chemotherapy because of local tumour progression (n = 5), treatments at other 61 
hospitals (n = 5), only palliative care (n = 2), die  during pre-operative chemotherapy (n 62 
= 1) or follow-up elsewhere (n = 1). The remaining 25 patients were included. We 63 
retrospectively reviewed the clinical records and imaging for these patients. The 64 
diagnosis was made following a review of the histopa hology and radiology at the 65 
multidisciplinary discussion. The diagnostic criteria for radiation-induced sarcoma of 66 
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bone was according to previous reports by Arlen et al. [1] and Cahan et al. [2]. All 67 
tumours were resected with the aim of achieving clear margins. An amputation was 68 
performed if it was not possible to obtain clear margins with limb-salvage surgery after 69 
careful review of the pre-operative imaging. The decision for pre-operative 70 
chemotherapy was made in consultation with medical oncologists and patients, taking 71 
into account the chemotherapy previously received and patients’ comorbidities. Margins 72 
were evaluated according to Enneking’s criteria [18]. Any patient with 73 
intralesional/marginal margins were assessed for further radiotherapy based on local 74 
tissue toxicities from previous radiotherapy doses on a case-by-case basis following 75 
discussion with clinical oncologists as part of themultidisciplinary team. Currently we a 76 
use a 3 Tesla MRI scanner as our cross-sectional imaging of choice. 77 
Kaplan-Meier analysis was used to estimate overall survival (OS), event-free 78 
survival (EFS), metastasis-free survival (MFS) and local recurrence-free survival 79 
(LRFS). OS was defined as the time from the diagnosis t  death by any cause and was 80 
censored at the date of the latest follow-up. EFS was defined as the time from diagnosis 81 
to either the date of the death or recurrence (local r distant) and was censored at the 82 
date of the latest follow-up. LRFS and MFS were defined as the time from the surgical 83 
procedure to local recurrence or metastasis and were c nsored at the date of the latest 84 
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follow-up or death. Prognostic factors were assessed using log-rank test. Categorical 85 
variables were compared between groups using chi-square tests; numerical variables 86 
were compared using Mann-Whitney U tests. A two-tailed probability (P) value of 87 
<0.05 was considered to be statistically significant. Statistical analyses were performed 88 
using SPSS version 22.0 (IBM, Armonk, NY). 89 
 90 
3. Results 91 
3.1 Patient demographics 92 
Table 1 shows patients’ previous tumours for which radiation therapy was performed. 93 
The most frequent previous tumour in this series waEwing’s sarcoma (n = 5, 20%). 94 
Radiation-induced sarcoma of bone occurred after a median 16 years (interquartile 95 
range [IQR], 11 to 20 years) following radiation therapy for previous tumours. 96 
Radiation doses were not available because of the length of the study period. There 97 
were 10 males and 15 females (Table 2). The median age at diagnosis of a 98 
radiation-induced sarcoma of bone was 42 years (IQR, 23 to 63 years). The most 99 
common site was the pelvis (n = 7, 28%). Histological diagnoses were osteosarcoma in 100 
19 patients and undifferentiated pleomorphic sarcoma in six, all categorized as high 101 
grade. Definitive surgical resection achieved limb-salvage surgery in 15 patients and 102 
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necessitated amputation in ten. The surgical margins achieved were radical in three 103 
patients, wide in ten, marginal in eight, intralesional in two patients and unavailable in 104 
two patients. 105 
Fourteen patients received (neo-)adjuvant chemotherapy. The 106 
chemotherapy-induced necrosis was ≥90% in three patients, <90% in eight and 107 
unavailable in three. The regimens varied: doxorubicin and cisplatin (n = 3), high dose 108 
methotrexate (HD-MTX), ifosfamide and etoposide (n = 2), HD-MTX, doxorubicin and 109 
cisplatin (n = 1), doxorubicin and ifosfamide (n = 1), vincristine, ifosfamide, 110 
doxorubicin and etoposide (n = 1) or no information (n = 6). Predisposing genetic 111 
diseases, such as Li-Fraumeni syndrome or bilateral r tinoblastoma, were not detected 112 
in this study group. No patient underwent further radiation therapy after surgery. 113 
 114 
3.2 Oncological outcomes 115 
The median follow-up time for all patients was 40 months (IQR, 14 to 192 months). The 116 
5-year OS, 5-year EFS and 5-year LRFS for all patients were 53% (95% CI 31% to 117 
70%), 40% (95% CI 21% to 59%) and 68% (95% CI 45% to 84%), respectively. 118 
Fourteen (56%) of 25 patients died at last follow-up.  119 
Eleven patients (44%) developed distant metastases aft r surgery with the most 120 
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frequent location being lung (82%). Of the 11 patients, nine died from metastases, one 121 
patient was alive with disease at final follow-up, while one patient underwent excision 122 
of two lung metastases after two months from initial definitive surgery and survived for 123 
218 months. 124 
Seven patients (28%) developed a local recurrence. Four of these patients had 125 
multiple lung metastases at the time of local recurrence and therefore did not undergo 126 
local treatments. Three patients did not have distant metastasis at the time of local 127 
recurrence and underwent a re-excision. The risk of local recurrence was 0% (0 of 3) 128 
with radical margins, 30% with wide margins (3 of 10), 38% with marginal margins (3 129 
of 8) and 50% (1 of 2) in intralesional margins. 130 
 131 
3.3 Prognostic factors 132 
Patients with wide or radical surgical margins (n = 13) showed significantly better OS 133 
compared with those with marginal (n = 8) or intralesional (n = 2) margins (5-year OS, 134 
radical or wide = 74%, marginal = 17%, intralesional = 0%, p = 0.044, Table 3 and Fig. 135 
1a). Local recurrences were significantly associated with worse OS (p = 0.006). Patients 136 
who received neo-adjuvant chemotherapy showed significa tly better MFS (p = 0.040). 137 
However, preoperative chemotherapy or chemotherapy-induced necrosis of ≥90% was 138 
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not significantly associated with better OS (p = 0.747, p = 0.659, respectively). 139 
 140 
3.4 Comparison of surgical and oncological outcomes between the limb-salvage 141 
group and the amputation group 142 
Table 4 shows patients demographics and outcomes in the limb-salvage group and the 143 
amputation group. 144 
 145 
Local recurrence:  146 
Local recurrence was the most common complication. Of the 15 patients who 147 
underwent limb-salvage surgery, seven (47%) patients developed local recurrence. 148 
Local recurrence occurred in 60% (3 of 5) of the pelvic cases, 75% (3 of 4) of the 149 
scapula cases and 17% (1 of 6) in long bone cases. Th  risk of local recurrence in the 150 
limb-salvage group was significantly higher compared to that of the amputation group 151 
(47% vs 0%, p = 0.011). The LRFS was significantly better in the amputation group 152 
compared to that of the limb-salvage group (5-year = 100% vs 49%, p = 0.017, Fig. 1b). 153 
In the limb-salvage group, risk of local recurrence was 50% (3 of 6) in patients with 154 
wide margin, 43% (3 of 7) in patients with marginal margin and 100% (1 of 1) in a 155 
patient with an intralesional margin. For local recurrence without distant metastasis, two 156 
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pelvic recurrences underwent secondary hindquarter mputation; one scapula recurrence 157 
underwent re-excision. Four patients with pulmonary metastases at restaging with local 158 
recurrence received palliative chemotherapy without local control after MDT 159 
discussion.  160 
 161 
Surgical site infection:  162 
No patients who underwent a primary amputation suffered surgical site infection. Three 163 
patients developed infection after limb-salvage surgery: one distal tibial endoprosthetic 164 
replacement was successfully treated with debridement and implant retention. One 165 
scapulectomy patient developed chronic infection necessitating secondary forequarter 166 
amputation. One distal femoral endoprosthetic replacement developed a superficial 167 
infection and was successfully treated with antibiocs alone.  168 
 169 
Overall complications and additional surgeries for complications:  170 
Of the 15 patients who underwent limb-salvage surgery, 11 (73%) developed at least 171 
one complication, which was significantly higher than the amputation group (10%, p = 172 
0.002). Similarly, the risk of additional surgeries for the management of complications 173 
was significantly higher in the limb-salvage group than that of the amputation group 174 
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(33% vs 0%, p = 0.041).  175 
 176 
Oncological outcomes:  177 
The 5-year OS and EFS were 37% and 37% in the limb-salvage group and 78% and 178 
45% in the amputation group, respectively. These were not significantly different (p = 179 
0.188 and p = 0.912, respectively). The 5-year MFS was 56% in the limb-salvage group 180 
and 45% in the amputation group (p = 0.452).  181 
 182 
4. Discussion 183 
We have reported the surgical and oncological outcomes and prognostic factors for 184 
non-metastatic, radiation-induced sarcoma of bone. Because many previous reports 185 
concerning radiation-induced sarcoma of bone are small case series often combined 186 
with radiation-induced soft-tissue sarcomas, it is d fficult to compare our results 187 
[1-5,19-23]. There are three reports that mainly focused on radiation-induced sarcoma 188 
of bone (Table 5). Tabone et al. [9] and Shaheen et al. [10] reported five-year OS as 189 
between 50% and 69% respectively, which is similar to our result (five-year OS, 53%). 190 
By contrast, Lewis et al. [11] reported very poor five-year OS (24%) with high rate of 191 
metastatic recurrences (73%). 192 
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In our analysis, wide or radical surgical margins were associated with 193 
improved survival outcomes. However, multivariate analyses were not performed 194 
because of the limited number in our study. Confounding factors as well as selection 195 
bias might have an effect on our results. Larger studies are needed to possibly gain a 196 
more valid conclusion. Our study also showed local recurrence was significantly 197 
associated with worse OS. Like other reports on conventional osteosarcoma [24-26], it 198 
is difficult to determine whether local recurrence causes a poor outcome or is simply an 199 
indicator of aggressive tumour biology. In our experience, 57% of patients had 200 
synchronous distant metastases at the time of restaging fter local recurrence. 201 
The main surgical challenge in radiation-induced sarcoma of bone is the 202 
difficulty of obtaining a clear margin. Our experience showed that the local recurrence 203 
rate was 47% in the limb-salvage group, which was higher than that previously report 204 
by Shaheen et al [10] (25%). Local recurrence in our st dy occurred in 60% (3 of 5) in 205 
pelvic cases, 75% (3 of 4) in scapula cases and 17% (  of 6) in long bone cases. This 206 
high local recurrence rate in our analysis is presumably related to the location of the 207 
tumours. Indeed, 60% of tumours are located in the pelvis and scapula in our series, 208 
while only 35% of tumours were located in the axial skeleton in the study by Shaheen et 209 
al. [10] Thijssens et al [16] also reported a high local recurrence rate (54%) after surgery, 210 
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including amputation and excision, for radiation-induced bone or soft tissue sarcomas. 211 
These high rates of local recurrence are possibly explained by the difficulty of 212 
identifying tumour planes using MRI due to tissue alter tion following radiotherapy 213 
[27]. In our experience, MRI highlighted the difficulty of detecting clear tumour 214 
margins due to the combination of scarring and radiotherapy changes. Although we 215 
evaluated the tumours using a combination of MRI, CT and PET, there remains an 216 
inherent difficulty to detect clear tumour margins  tissues following radiation therapy. 217 
It is hoped that advancement in imaging modalities may provide clearer anatomical 218 
relationships in tissues exposed to radiotherapy. Radiation-induced fibrosis also makes 219 
it difficult for surgeons to palpably detect the true tumour margin. Furthermore, 220 
dissection of normal vessels and/or nerves away from the tumour during resection is 221 
also challenging post radiotherapy.  222 
Our experience showed that 20% of patients in the limb-salvage group 223 
developed infection, while no patients developed an infection in the amputation group. 224 
The wound complication rate, including infection, has been reported to be 17% (2 of 225 
12) after limb-salvage surgery for radiation-induced sarcoma of bone [10]. High rates 226 
(30%) of wound problems associated with excisions of soft tissue sarcomas after 227 
preoperative radiation therapy are well documented [28]. Radiation damage leads to 228 
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defective collagen deposition by the irradiated fibroblasts [12-14], which hinders repair 229 
of the wound. Moreover, the resection of normal fat or muscle, to obtain a margin, 230 
during surgery can impair the blood supply of skin over the surgical site. This would 231 
explain the high risk of infection in the limb-salvge group, compared to the amputation 232 
group where skin closure uses normal tissue with an abundant blood supply. 233 
Surgeons and patients need to make complex decisions in the surgical 234 
treatment of non-metastatic radiation-induced sarcoma f bone. Although limb-salvage 235 
surgery was significantly associated with high rates of local recurrence and 236 
postoperative complications, OS and EFS were not significantly different between the 237 
limb-salvage group and the amputation group. However, even if a wide margin was 238 
obtained, 50% of the patients subsequently developed local recurrence after 239 
limb-salvage surgery. We recommend careful discussion about the high risks of local 240 
recurrence and complications when choosing limb-salvage surgery. This study is the 241 
first to report comparative, quantitate data about the rates of local recurrence, 242 
postoperative complications, including additional surgeries for complications, between 243 
limb-salvage and amputation in this subset of patients. Our data can help the surgeon 244 
and patient to select a surgical procedure based on predicted risks for non-metastatic, 245 
radiation-induced sarcoma of bone. 246 
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It is difficult to discuss the benefit of preoperative chemotherapy because a 247 
variety of regimens were used in our study. This is because chemotherapy protocols for 248 
radiation-induced sarcoma of bone are not standardized and are affected by previous 249 
chemotherapy treatment. Tabone et al [9] concluded patients with resectable 250 
radiation-induced osteosarcoma can be cured with surgery and intensive neo-adjuvant 251 
chemotherapy based on their experience in 16 patients. Bielack et al [23] also reported 252 
that the treatment of secondary osteosarcoma, including radiation-induced osteosarcoma, 253 
with neoadjuvant chemotherapy and surgery had a prognosis which approaches that of 254 
primary osteosarcoma. In our study, preoperative chemotherapy was related to better 255 
MFS. However, chemotherapy-induced necrosis did not have a significant correlation 256 
with OS and MFS, which is comparable with the previous report by Lewis et al [11]. 257 
Our current first choice of chemotherapeutic drugs for patients with radiation-induced 258 
sarcoma of bone is methotrexate, doxorubicin and cisplatin (MAP) 259 
neo-adjuvant/adjuvant chemotherapy. However, each patient needs to be assessed 260 
carefully by a specialist oncologist within a multidisciplinary team to determine the 261 
potential risks and benefits of neo-adjuvant/adjuvant chemotherapy, paying particular 262 
attention to the previous treatment regimes used to manage past malignancies. 263 
There are several limitations in our study including small sample size and 264 
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retrospective nature of the study. However this is one of the largest series to report 265 
non-metastatic, radiation-induced sarcoma of bone. 266 
 267 
5. Conclusion  268 
We believe that non-metastatic, radiation-induced sarcoma of bone should be resected 269 
aiming to achieve wide or radical surgical margins. Limb-salvage surgery showed 270 
higher local recurrence and postoperative complication rates compared to amputation. 271 
However, OS and EFS were not significantly different between two groups. 272 
 273 
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Figure legend 278 
Figure 1. 279 
a) Kaplan-Meier curves of overall survival for all patients stratified by surgical 280 
margins. 281 
b) Kaplan-Meier curves of local recurrence-free survival comparing limb-salvage 282 
group and an amputation group. 283 
284 
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Table 1. Previous tumours 363 
Total N % 
Ewing’s sarcoma 5 20 
Breast cancer 4 16 
Non Hodgkin lymphoma 4 16 
Rhabdomyosarcoma  3 12 
Osteosarcoma 2 8 
Cervix cancer 2 8 
Prostate cancer 1 4 
Undifferentiated pleomorphic sarcoma 1 4 
Giant cell tumour of bone 1 4 
Ovarian teratoma 1 4 




Table 2. Patient demographics 366 





Median age (years, IQR)   
 
42 (23 to 63) 
 
Sex  Male   10 40  
 
Female  15 60  
Median size (cm, IQR) 
 
11 (7.5 to 15) 
 
Pathological diagnosis Osteosarcoma 19 76  
 
Undifferentiated pleomorphic sarcoma 6 24  
Part of tumour Pelvis 7 28  
 
Femur 5 20  
 
Humeurs 5 20  
 
Tibia 4 16  
 
Scapula 4 16  
Procedure Excision 7 28  
 
Excision + endoprosthesis 8 32  
 
Hindquarter amputation 3 12  
 
Above knee amputation 5 20  
 
Forequarter amputation 2 8  
Margin Radical 3 12 
 Wide 10 40 
 Marginal 8 32 
 Intralesional 2 8 
 Not available 2 8 
Preoperative chemotherapy 
 
14 56  
Necrosis after chemotherapy ≥90% 3 21  
 
<90% 8 58  
 
Not available 3 21  
Local recurrence 
 
7 28  
Status at last follow-up Continuously disease-free 9 36  
 
No evidence of disease 1 4  
 
Alive with disease 1 4  
 
Death of sarcoma 11 44  
 
Death of unknown cause 2 8  
 
Death of heart disease 1 4  
Median follow-up (months, IQR)   40 (14 to192)   
IQR, Interquartile range 
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Table 3. Prognostic factors for overall survival (OS) and local recurrence-free survival (LRFS) 367 
    N 5-year OS (%) p value 5-year LRFS (%) p value 
Age (years) ≤40 12 56  0.775  64 0.908 
 
>40 13 50  
 
75  
Sex Male 10 36  0.143  80 0.351 
 
Female 15 80  
 
58  
Size (cm) ≤8 6 60  0.618  80 0.958 
 
>8 12 53  
 
80  
 Not available 7     
Site Pelvis 7 43  0.368  51 0.407 
 
Others 18 58  
 
77  
Preoperative chemotherapy Yes 14 57  0.747  70 0.802 
 
No 11 48  
 
69  
Chemotherapy-induced necrosis (%) <90 9 56  0.659  64 0.296 
 
≥90 3 67  
 
100  
 Not available 13     
Limb salvage  No 10 69  0.188  100 0.017 
 
Yes 15 38  
 
49  
Latency period (years) <15 9 44  0.100  70 0.454 
 
≥15 11 80  
 
90  
 Not available 5     
Local recurrence Yes 7 0 0.006 Not available  
 
No 18 71  
 
Not available  
Margin Radical or wide 13 74  0.044  75 0.707 
 
Marginal 8 38  
 
60  
  Intralesional 2 0    0  
 Not available 2     
 27 
Table 4. Comparison of patient demographics and outcomes between the limb-salvage group and the amputation group 368 







Gender Male 10 5 33  5  50  0.405  
 
Female 15 10 67  5  50  
 







Site Pelvis 7 5 33 2  20  0.162  
 
Femur 5 1 7 4  40  
 
 
Humeurs 5 3 20  2  20  
 
 
Tibia 4 2 13  2  20  
 
 
Scapula 4 4 27  0  0  
 
Margin Radical 3 0 0 3 30 0.067 
 
Wide 10 6 40 4 40  
 
Marginal 8 7 46 1 10  
 
Intralesional 2 1 7 1 10  
 Not available 2 1 7 1 10  
Complications Local recurrence 7 7 47  0 0  0.011  
 
Infection 3 3 20 0  0  0.132  
 
Dislocation 1 1 7 0 0  0.405  
 
Delayed wound healing 1 0 0  1 10  0.211  
 
Aseptic loosening 1 1 7  0 0  0.405  
 
At least one complication 12 11 73  1 10  0.002  
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Surgery for complication Secondary amputation 3 3 20  0 0  0.132  
 
Debridement 1 1 7  0 0  0.405  
 
Revision for aseptic loosening 1 1 7  0 0  0.405  
 
At least one surgery for complication 5 5 33  0 0  0.041  







5-year event-free survival (%)   37  45  0.912 









Table 5.  Summary of the comparative literature 371 
















Tabone et al9 1999 23 OS (23) 20 (87) 16 (70) 14 (61) 14 (61) NA NA NA 8yr, 50% NA 
Shaheen et al10 2006 24 
OS (17), UPS (4), CS 
(1), FS (1), LMS (1) 
18 (75) 20 (83) 14 (58) 12 (50) 3 (25) 2 (10) 50% 5yr, 69%* NA 
Lewis et al11 2006 27 OS (27) 26 (96) 27 (100) 22 (81) 21 (78) NA NA 73% 5yr, 24% Long latency period 
Current paper 2018 25 OS (19), UPS (6) 25 (100) 25 (100) 14 (56) 15 (60) 7 (47) 3 (12) 44% 5yr, 53% 
Wide or radical 
margin  
* Ten patients with non-metastatic tumour who received chemotherapy and surgery 
OS, osteosarcoma; UPS, undifferentiated pleomorphic sar oma; CS, Chondrosarcoma; FS, fibrosarcoma; LMS, leiomyosarcoma; LSS, limb-salvage surgery; LR, loca  recurrence; SSI, surgical site infection; NA, 
not available 
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